BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/24/2022 11:31:49 AM | Browse: 250 | Download: 465
 |
Received |
|
2022-01-31 22:30 |
|
Peer-Review Started |
|
2022-01-31 22:31 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-06-19 23:25 |
|
Revised |
|
2022-07-02 16:15 |
|
Second Decision |
|
2022-07-18 03:04 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2022-07-22 04:13 |
|
Articles in Press |
|
2022-07-22 04:13 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-08-03 10:32 |
|
Publish the Manuscript Online |
|
2022-08-24 11:31 |
| ISSN |
1948-9366 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Sirolimus vs tacrolimus: Which one is the best therapeutic option for patients undergoing liver transplantation for hepatocellular carcinoma?
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Faiza Ahmed, Faiza Zakaria, Godsgift Enebong Nya and Mohamad Mouchli |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Faiza Ahmed, BSc, MD, MSc, Instructor, Research Scientist, Senior Researcher, Division of Clinical and Translational Research, Larkin Community Hospital-Larkin Healthcare Systems, 7031 SW 62nd Ave, South Miami, FL 33143, United States. dr.faiza.ahmed11@gmail.com |
| Key Words |
Rapamycin; Tacrolimus; Sirolimus; Immunosuppressants; Hepatocellular carcinoma; Liver transplantation |
| Core Tip |
Post-transplant rejection holds significance in the long-term survival of patients with hepatocellular carcinoma (HCC) receiving a liver transplant (LT). The role of the mammalian target of rapamycin inhibitor (mTOR inhibitors) in preventing HCC recurrence after LT is still under debate. The major goal of this letter is to summarize the most relevant existing data on sirolimus, an mTOR inhibitor, and tacrolimus, a calcineurin inhibitor, therapy involvement in the progression of such patients. |
| Publish Date |
2022-08-24 11:31 |
| Citation |
Ahmed F, Zakaria F, Enebong Nya G, Mouchli M. Sirolimus vs tacrolimus: Which one is the best therapeutic option for patients undergoing liver transplantation for hepatocellular carcinoma? World J Gastrointest Surg 2022; 14(8): 862-866 |
| URL |
https://www.wjgnet.com/1948-9366/full/v14/i8/862.htm |
| DOI |
https://dx.doi.org/10.4240/wjgs.v14.i8.862 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
